Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.570
-0.160 (-4.29%)
Dec 3, 2024, 12:09 PM EST - Market open
Agenus Revenue
Agenus had revenue of $25.11M in the quarter ending September 30, 2024, with 3.28% growth. This brings the company's revenue in the last twelve months to $160.43M, up 59.00% year-over-year. In the year 2023, Agenus had annual revenue of $156.31M with 59.47% growth.
Revenue (ttm)
$160.43M
Revenue Growth
+59.00%
P/S Ratio
0.48
Revenue / Employee
$412,409
Employees
389
Market Cap
83.75M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
electroCore | 23.33M |
BioAtla | 11.00M |
WORK Medical Technology Group LTD | 9.86M |
Clearside Biomedical | 7.70M |
Ovid Therapeutics | 631.70K |
AGEN News
- 6 days ago - Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
- 21 days ago - Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development - Business Wire
- 26 days ago - Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 - Business Wire
- 4 weeks ago - Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
- 4 weeks ago - November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm - Accesswire
- 4 weeks ago - The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Agenus Inc. - Accesswire
- 4 weeks ago - Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm - Accesswire